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Background: The transactivator of transcription (Tat) protein of human immunodeficiency virus type 1 (HIV-1) is known to
undergo ubiquitination. However, the roles of ubiquitination in regulating Tat stability and activities are unclear. In addition,
although the 72- and 86-residue forms are commonly used for in vitro studies, the 101-residue form is predominant in the
clinical isolates of HIV-1. The influence of the carboxyl-terminal region of Tat on its functions remains unclear.
Results: In this study, we find that Tat undergoes lysine 48-linked ubiquitination and is targeted to proteasome-dependent
degradation. Expression of various ubiquitin mutants modulates Tat activities, including the transactivation of transcription,
induction of apoptosis, interaction with tubulin, and stabilization of microtubules. Moreover, the 72-, 86- and 101-residue
forms of Tat also exhibit different stability and aforementioned activities.
Conclusions: Our findings demonstrate that the ubiquitination and carboxyl-terminal region of Tat are critical determinants
of its stability and activities.
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The HIV-1 transactivator of transcription Tat undergoes
multiple posttranslational modifications, including acetyl-
ation, methylation, and ubiquitination, which regulate Tat-
mediated transactivation of HIV long terminal repeat
(LTR) [1-8]. Tat acetylation has been well characterized to
be fine-tuned by histone acetyltransferases (HATs) and his-
tone deacetylases (HDACs) at specific lysine residues and
is involved in the regulation of Tat activities [1,4,9-14]. The
mutation of certain lysine residues in Tat significantly af-
fects Tat activities such as transactivation of transcription
and induction of apoptosis [15]. Given that ubiquitination
is another posttranslational modification of lysine residues,
it is reasonable to speculate that the influences on Tat
activities caused by lysine mutation may be partially at-
tributed to altered ubiquitination of Tat.
In support of this speculation, Tat has been reported to
be subjected to ubiquitination [2]. According to the previ-
ous study, Tat undergoes lysine 63-linked ubiquitination* Correspondence: dwli@nankai.edu.cn
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unless otherwise stated.mediated by the proto-oncoprotein Hdm2, which further
regulates Tat transactivation activity through a non-
proteolytic pathway [2]. Modification of Tat by lysine
63-linked polyubiquitin chains does not affect Tat sta-
bility [2]. Whether the stability of Tat is modulated by
the ubiquitin-proteasome system, either through the
canonical lysine 48-linked ubiquitination or the non-
canonical signals such as lysine 29-linked ubiquitina-
tion [16], remains to be determined. Besides, the roles
of ubiquitination in the regulation of the diverse func-
tions of Tat are largely unknown.
The full-length 101-residue form of Tat (hereafter,
Tat101 or just Tat) is encoded by HIV-1 tat gene com-
posed of two exons. The first exon encodes a truncated
form of Tat with only the first 72 amino acids (hereafter
Tat72). It is generated in the late stage of HIV-1 infection
cycle. The 86-residue truncated form of Tat (hereafter
Tat86), produced early in HIV-1 infection, is generated
due to a premature stop codon within the second exon.
Though the full-length form of Tat is predominant in
HIV-1 clinical isolates [17], Tat86 and Tat72 are more
widely used for in vitro studies, leaving the carboxyl-
terminal region unconsidered.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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nificance of the carboxyl-terminal region of Tat for its
activities [18-21]. For instance, the second exon of tat
gene has been demonstrated to have an important func-
tion for in vivo replication [18]. Additionally, Tat101 and
Tat86 have been reported to be distinct from each
other in the abilities of transactivation of HIV-1 LTR
and induction of apoptosis of T cells [19]. However, a
detailed and systematic comparison of the activities of
the full-length Tat and two truncated forms is still
needed to fully decipher the biological importance of
the carboxyl-terminal region of Tat in the regulation of
its functions.
In this study, we provide the first evidence that Tat
undergoes lysine 48-linked ubiquitination and is targeted
to proteasome-dependent degradation. Expression of vari-
ous ubiquitin mutants modulates diverse activities of Tat.
In addition, we find that the stability and activities of the
72-, 86- and 101-residue forms of Tat are distinct. Our
results suggest that the ubiquitination and carboxyl-
terminal region of Tat are involved in the regulation of
Tat stability and activities.
Results
The ubiquitination and carboxyl-terminal region of Tat
regulate the stability of Tat
To investigate the roles of the ubiquitination and
carboxyl-terminal region of Tat in the regulation of its
stability, we firstly constructed GFP-tagged full-length Tat
(GFP-Tat101) and the truncated forms (GFP-Tat86 and
GFP-Tat72) as shown in Figure 1A. By immunoprecipita-
tion assays, we confirmed that Tat was subjected to
ubiquitination when cotransfected with His-Myc-tagged
wild-type (WT) ubiquitin but not the ubiquitin-K0 mutant
(Figure 1B). To further determine the type of polyubiqui-
tin linkage with which Tat is modified, we constructed
ubiquitin-K29, -K48, and -K63 mutants which contain
only a single lysine (K29, K48, and K63, respectively) with
all the other lysines mutated to arginine. As shown in
Figure 1C, ubiquitination of Tat could only be detected
in ubiquitin-K48 mutant cotransfection group, but was
much weaker as compared to ubiquitin-WT group.
This indicates that other types of Tat ubiquitination may
exist though they were not observed by our approach. We
still examined the effects of ubiquitin-K29 and -K63 mu-
tants on Tat activities through cotransfection.
To evaluate the effects of Tat ubiquitination on its sta-
bility, 293 T cells were cotransfected with GFP-Tat101
and various ubiquitin mutants and treated with or with-
out the proteasome inhibitor MG132 for 8 hours before
collection. No substantial effect on Tat levels was ob-
served by MG132 treatment except for the ubiquitin-
K48 mutant cotransfection group (Figure 1D and E),
which indicated that the lysine 48-linked ubiquitinationof Tat targeted it to proteasome-dependent degradation.
However, Tat in ubiquitin-WT cotransfection group
showed little response to MG132 treatment. This might
be due to the fact that lysine 48-linked ubiquitination is
not the dominant type of ubiquitination of Tat, which
has been indicated by Figure 1C. The ubiquitin-K48 mu-
tant contains only a single lysine with all the other ly-
sines mutated to arginine, while the wild-type ubiquitin
contains 7 lysines. The other lysines in wild-type ubiquitin
may competitively inhibit lysine 48-linked ubiquitination
and proteasome-dependent degradation of Tat (Figure 1D,
lane 1 vs lane 7).
We next assessed the influence of the carboxyl-terminal
region of Tat on its stability. According to our data,
MG132 treatment had little effect on the protein level of
Tat101, only slightly affected that of Tat86, but increased
that of Tat72 by nearly 45% (P < 0.0001) (Figure 1F and G).
By quantitative real-time PCR, we found that the mRNA
levels of Tat101, Tat86, and Tat72 were not significantly
changed by MG132 treatment (Figure 1H). This finding
suggests that the carboxyl-terminal region truncation of
Tat makes it fragile and sensitive to proteasome-dependent
degradation. Collectively, these results demonstrate that
the stability of Tat is modulated by its ubiquitination and
carboxyl-terminal region.
The ubiquitination or carboxyl-terminal region of Tat has
little effect on its subcellular localization
Given that posttranslational modification may influence
protein subcellular localization, and the distribution pat-
terns vary among different variants of certain proteins, we
asked whether the ubiquitination or carboxyl-terminal re-
gion of Tat affects its distribution. HeLa cells were trans-
fected with the indicated plasmids and examined by
fluorescence microscopy. The nuclear localization of Tat
was quantified via ImageJ software by measuring the ratio
of GFP intensity inside the nucleus over that in the whole
cell.
No substantial difference in Tat localization was ob-
served when full-length Tat was cotransfected with vari-
ous ubiquitin mutants in the absence or presence of
MG132 (Figure 2A and B). Full-length Tat and the two
truncated variants displayed similar distribution patterns
with a slight decrease in nuclear localization of the trun-
cated forms, and MG132 caused no remarkable changes
(Figure 2C and D). Altogether, these observations sug-
gest that the ubiquitination or carboxyl-terminal region
of Tat has little effect on its localization.
Tat transactivation activity is modulated by its
ubiquitination and carboxyl-terminal region
It has been reported that posttranslational modifica-
tions of Tat, such as acetylation, methylation and phos-
phorylation, regulate its transactivation activity [22].
Figure 1 The ubiquitination and carboxyl-terminal region of Tat regulate the stability of Tat. (A) Schematic representation and functional
domains of HIV-1 Tat and schematic diagrams of GFP-tagged Tat101 and two truncated mutants. CRD, cysteine-rich domain; Core, conserved core
region; Basic, region of basic amino acids; QRD, glutamine-rich domain; RGD, region of Arg-Gly-Asp sequence. (B and C) 293 T cells were cotransfected
with GFP-Tat101 and His-Myc-tagged WT ubiquitin or the lysine mutants (K0, K29, K48, and K63) and treated with MG132. Anti-GFP immunoprecipitates
and cell lysates were immunoblotted with anti-Myc or anti-GFP antibodies. (D) 293 T cells were cotransfected with GFP-Tat101 and His-Myc-tagged WT
ubiquitin or the lysine mutants and treated with (+) or without (−) MG132. Cell lysates were subjected to immunoblot analysis with antibodies against
GFP or α-tubulin. Anti-α-tubulin western blot was done as a loading control. (E) Quantification of the results in (D). Bars represent the relative ratios of
GFP over α-tubulin levels normalized to the untreated ubiquitin-K0 mutant transfection group. (F) 293 T cells were transfected with GFP-Tat101,
GFP-Tat86, GFP-Tat72 or GFP alone and treated with (+) or without (−) MG132. Cell lysates were immunoblotted with anti-GFP or anti-α-tubulin
antibodies. (G) Quantification of the results in (F). Bars represent the relative ratios of GFP over α-tubulin levels normalized to the untreated GFP vector
transfection group. (H) Quantitative real-time PCR analysis of gene expression in 293 T cells transfected with GFP-Tat101, GFP-Tat86, or GFP-Tat72 and
treated with (+) or without (−) MG132. GAPDH was used for normalization. Two-tailed Student’s t-test for all graphs. *P < 0.05, **P <0.01, ***P < 0.001;
ns, not significant. Mean and standard deviations were derived from three independent biological replicates. Cropped blots are used in this figure, and
the gels were run under the same experimental conditions.
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cant difference in the transactivation activities of full-length
Tat and the truncated variant Tat86 [19]. We thus systemat-
ically analyzed the effects of the ubiquitination and carboxyl-
terminal region of Tat on its transactivation activity.
Compared to the untreated ubiquitin-K0 cotransfec-
tion group, cotransfection with ubiquitin-WT or -K63
led to a five- or three-fold increase in Tat transactivation
activity respectively, while cotransfection with ubiquitin-K29 or -K48 caused only a slight increase (Figure 3A).
The addition of MG132 showed no considerable effect
on Tat transactivation activity in ubiquitin-K0, -K29
and -K63 cotransfection groups, but brought about oppos-
ite effects in ubiquitin-WT and -K48 groups (Figure 3A).
However, the results of statistical analysis indicated that
the changes of transactivation activity caused by MG132
treatment in ubiquitin-WT cotransfection groups were not
significant (P = 0.1183).
Figure 2 The ubiquitination or carboxyl-terminal region of Tat has little effect on its subcellular localization. (A) HeLa cells were
cotransfected with GFP-Tat101 and His-Myc-tagged WT ubiquitin or the lysine mutants and treated with (+) or without (−) MG132. Cells were
then stained with the DNA dye DAPI. The subcellular localization of GFP-Tat101 was examined by fluorescence microscopy. (B) Experiments
were performed as in (A), and the percentage of nuclear GFP-Tat101 was quantified via ImageJ software. Bars represent the relative folds
normalized to the untreated ubiquitin-K0 mutant transfection group. Experiments were done in duplicate and results were expressed as the
mean ± SD. (C) HeLa cells were transfected with GFP-Tat101, GFP-Tat86, GFP-Tat72 or GFP alone and treated with (+) or without (−) MG132.
Cells were then subjected to nuclear staining with DAPI. The subcellular localization of GFP alone or GFP fusion proteins was analyzed by fluorescence
microscopy. (D) Experiments were performed as in (C), and the percentage of nuclear GFP or GFP fusion proteins was quantified via ImageJ
software. Bars represent the relative folds normalized to the untreated GFP vector transfection group. Experiments were done in duplicate
and results were expressed as the mean ± SD.
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Tat on its transactivation activity, luciferase reporter as-
says were performed and the results revealed that full-
length Tat and the two truncated mutants resembled
each other in transactivation ability in the absence of
MG132 (Figure 3B). Intriguingly, MG132 exerted slight
effect on the transactivation activity of Tat101 or Tat86, but
markedly increased that of Tat72 (P = 0.0043) (Figure 3B).
These findings together indicate that Tat transactivation ac-
tivity is regulated by its ubiquitination and carboxyl-terminal
region.
The ability of Tat to induce apoptosis is regulated by its
ubiquitination and carboxyl-terminal region
Tat acetylation has been characterized to be involved in the
regulation of Tat-mediated apoptosis [15,23]. Moreover,
Tat86 has been reported to trigger slightly more apoptosis
in CD4+ T cells than the full-length form [19]. We thus ex-
amined the influences of Tat ubiquitination on its induc-
tion of apoptosis, and further compared the abilities of
Tat101 and the two truncated forms to trigger apoptosis.
By fluorescence microscopic analysis of cell morphology
of GFP-positive cells, we found that cotransfection with
ubiquitin-K29 and -K63 led to about 40% increase of cell
shrinkage and cell membrane shriveling [24] when com-
pared to the untreated ubiquitin-K0 cotransfection group
(Figure 4A and B). The addition of MG132 led to about40% increase of apoptosis in ubiquitin-K48 cotransfection
groups, but caused no notable changes in other groups
(Figure 4A and B). By Annexin V-APC staining coupled
with flow cytometry, we found that cotransfection with
ubiquitin-K29 caused a more than 2-fold increase of
Tat-induced apoptosis than the other four groups in
the absence of MG132 (Figure 4C and D). The addition
of MG132 led to slight changes of Tat-induced apop-
tosis in ubiquitin-K0 or ubiquitin-K29 cotransfection
groups, moderate increases in ubiquitin-K48 or ubiquitin-
K63 cotransfection groups, and significant increases in
ubiquitin-WT cotransfection groups (Figure 4C and D).
The slight differences between the results of the two apop-
tosis analysis assays may be caused by manual counting in
the former assay, which relies on subjective judgments to
a certain extent.
Given that activation of caspase-3 is involved in the
process of Tat-induced apoptosis [25], we then assessed
the percentage of cleaved caspase-3 (the active form of
caspase-3) positive cells 96 hours post-transfection. As
shown in Figure 4E, HeLa cells with overexpressed GFP-
Tat101, which were positive for cleaved caspase-3, were
indicated by hollow arrows. The percentage of cleaved
caspase-3 positive cells in ubiquitin-K29 cotransfection
group was higher than that of the other four groups in the
absence or presence of MG132 respectively (Figure 4F),
which concurred with the results in Figure 4B and D.
Figure 3 Tat transactivation activity is modulated by its ubiquitination and carboxyl-terminal region. (A) 293 T cells were cotransfected
with an HIV-1 LTR-driven luciferase plasmid, a GFP-Tat101 plasmid, and various ubiquitin mutants and treated with or without MG132. Luciferase
activity was then measured and normalized to GFP intensity. Bars represent the relative folds of transactivation activity obtained from two
experiments done in triplicate and normalized against the untreated ubiquitin-K0 mutant transfection group. Results were expressed as
the mean ± SD. (B) 293 T cells were cotransfected with an HIV-1 LTR-driven luciferase plasmid and plasmids expressing GFP fusion proteins or
GFP alone and treated with or without MG132. The relative folds of transactivation activity were obtained as in (A). Results were expressed as the
mean ± SD. Two-tailed Student’s t-test for all graphs. *P < 0.05, **P <0.01, ***P < 0.001; ns, not significant.
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ubiquitin-K63 led to an increase in Tat-induced apoptosis
when compared to the ubiquitin-K0 cotransfection groups
(Figure 4F), which concurred with the data in Figure 4D.
With similar approaches, we assessed the effects of the
carboxyl-terminal region of Tat on its ability to induce
apoptosis. By fluorescence microscopy and flow cytome-
try, we found that Tat72 was the most potent variant ofTat to trigger apoptosis (Figure 5A-D). The induction of
apoptosis by the three forms of Tat was scarcely affected
by MG132 treatment (Figure 5D). Immunoblot analysis
and immunofluorescence microscopy also showed that
GFP-Tat72 overexpression caused the most robust acti-
vation of caspase-3 (Figure 5E-G). Thus, these results in-
dicate that Tat-induced apoptosis is regulated by its
ubiquitination and carboxyl-terminal region.
Figure 4 Tat-induced apoptosis is regulated by its ubiquitination. (A) HeLa cells were cotransfected with GFP-Tat101 and His-Myc-tagged
WT ubiquitin or the lysine mutants. 72 hours post-transfection, cells were treated with (+) or without (−) MG132 and incubated for additional
24 hours. Apoptotic cells were examined via the fluorescence microscope by analyzing cell morphology of GFP-positive cells. (B) Quantification of
the results in (A). The number of apoptotic cells was counted and the percentage of apoptotic cells was calculated. Bars represent the relative
folds of Tat-induced apoptosis normalized to the untreated ubiquitin-K0 mutant transfection group. Experiments were done in duplicate, six fields
per group were counted, and the results were expressed as the mean ± SD. (C) HeLa cells were transfected and treated as in (A), and the apoptotic
cells were examined by Annexin V-APC staining coupled with flow cytometry. Mock transfected HeLa cells without Annexin V-APC staining were used
as negative control (NC). (D) Quantification of the results in (C). Bars represent the relative folds of Tat-induced apoptosis normalized to the untreated
ubiquitin-K0 mutant transfection group. Mean and standard deviations were derived from two independent experiments done in duplicate. (E) HeLa
cells were transfected and treated as in (A), and stained with anti-cleaved caspase-3 antibodies and the DNA dye DAPI. Apoptotic cells were indicated
by hollow arrows. (F) Quantification of the results in (E). Bars represent the relative folds of Tat-induced apoptosis normalized to the untreated
ubiquitin-K0 mutant transfection group. Experiments were done in duplicate, 80 GFP-positive cells per group were counted, and the results were
expressed as the mean ± SD. Two-tailed Student’s t-test for all graphs. *P < 0.05, **P <0.01, ***P < 0.001; ns, not significant.
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fluence its activity towards microtubule assembly
Previous studies have elucidated that Tat directly inter-
acts with tubulin dimers and microtubules, which alters the
microtubule dynamics and contributes to Tat-induced apop-
tosis [23,25-29].We hypothesized that the ubiquitinationand carboxyl-terminal region of Tat might regulate Tat-
induced apoptosis by modulating its activity towards micro-
tubule assembly.
To test this hypothesis, we firstly examined the inter-
action between Tat and tubulin in response to the ubi-
quitination or carboxyl-terminal region truncation of
Figure 5 Tat-induced apoptosis is modulated by its carboxyl-terminal region. (A) HeLa cells were transfected with GFP-Tat101, GFP-Tat86,
GFP-Tat72 or GFP alone. 72 hours post-transfection, cells were treated with (+) or without (−) MG132 and incubated for additional 24 hours. Apoptotic
cells were examined via the fluorescence microscope by analyzing cell morphology of GFP-positive cells. (B) Quantification of the results in (A). Experiments
were done in duplicate, six fields per group were counted, and the results were expressed as the mean± SD. (C) HeLa cells were transfected and treated as
in (A), and the apoptotic cells were examined by Annexin V-APC staining coupled with flow cytometry. (D) Quantification of the results in (C). Bars represent
the relative folds of Tat-induced apoptosis normalized to the untreated GFP vector transfection group. Mean and standard deviations were derived from two
independent experiments done in duplicate. (E) HeLa cells were transfected and treated as in (A) and collected 96 hours post-transfection. Cell lysates were
subjected to immunoblot analysis with antibodies specific for cleaved caspase-3, α-tubulin, or GFP, respectively. (F) HeLa cells were transfected and treated as
in (A), and stained with anti-cleaved caspase-3 antibodies and the DNA dye DAPI. Apoptotic cells were indicated by hollow arrows. (G) Quantification of the
results in (F). Bars represent the relative folds of Tat-induced apoptosis normalized to the untreated GFP vector transfection group. Experiments
were done in duplicate, 80 GFP-positive cells per group were counted, and the results were expressed as the mean ± SD. Two-tailed Student’s t-test
for all graphs. *P < 0.05, **P <0.01, ***P < 0.001; ns, not significant. Cropped blots are used in this figure, and the gels were run under the
same experimental conditions.
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fection with ubiquitin-K48 or -K63 mutants dramatically
diminished the interaction of Tat with tubulin as compared
to the K0 group (Figure 6A). MG132 treatment remarkably
enhanced the Tat-tubulin interaction in WT group, but
only slightly increased their interaction in ubiquitin-K48 or
-K63 groups (Figure 6A). Surprisingly, among the three var-
iants of Tat, Tat86 displayed the strongest interaction with
tubulin (Figure 6B). Only the interaction between Tat72and tubulin was notably enhanced by the treatment of
MG132 (Figure 6B).
We then investigated the effects of the ubiquitination
and carboxyl-terminal region of Tat on its activity towards
microtubule assembly. Protein samples containing soluble
tubulin (S), polymerized microtubules (P) or a mixture of
both (T) were prepared from HeLa cells transfected with
the indicated plasmids (Figure 6C) and analyzed by immu-
noblot. Compared with the K0 group, cotransfection with
Figure 6 The ubiquitination and carboxyl-terminal region of Tat influence its activity towards microtubule assembly. (A) Anti-GFP
immunoprecipitates and cell lysates were immunoblotted with anti-α-tubulin or anti-GFP antibodies. (B) 293 T cells were transfected with GFP-Tat101,
GFP-Tat86, GFP-Tat72 or GFP alone and treated with (+) or without (−) MG132. Anti-GFP immunoprecipitates and cell lysates were subjected to
immunoblot analysis with antibodies against α-tubulin or GFP. (C) Schematic representation of the experimental workflow. Upon transfection of
HeLa cells with the indicated plasmids, half the cells were boiled in SDS-PAGE sample buffer to obtain a mixture of soluble tubulin and polymeric
fraction (microtubules) as total tubulin (T). The other half were subjected to the preparation of soluble tubulin (S) and polymeric fraction (P)
as described in Materials and Methods. (D) HeLa cells were cotransfected with GFP-Tat101 and various ubiquitin mutants and treated with
(+) or without (−) MG132. Protein samples were prepared as in (C) and immunoblotted with antibodies against α-tubulin or GFP. The ratios
of polymeric fraction over soluble tubulin (P/S) were normalized against total tubulin levels and GFP intensity, and the relative folds were
normalized to the untreated ubiquitin-K0 mutant transfection group and shown under the corresponding blots. (E) HeLa cells were transfected
with GFP-Tat101, GFP-Tat86, GFP-Tat72 or GFP alone and treated with (+) or without (−) MG132. Protein samples were prepared as in (C) and analyzed
as in (D). Cropped blots are used in this figure, and the gels were run under the same experimental conditions.
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bules, which was further promoted by the addition of
MG132 (Figure 6D). Curiously, the effect of ubiquitin-K63
on Tat stabilization of microtubules was sharply changed
by MG132 treatment, from inhibition to promotion
(Figure 6D). In addition, the two truncated forms of
Tat showed weaker microtubule-stabilizing abilities
with limited response to MG132 treatment (Figure 6E).
Nevertheless, a two-fold increase in microtubule-stabilizing
activity of full-length Tat by MG132 treatment was ob-
served in this set of experiments (Figure 6E). Taken to-
gether, these data demonstrate that the activity of Tat
towards microtubule assembly is affected by its ubiquitina-
tion and carboxyl-terminal region.
Discussion
Emerging evidence suggests that posttranslational modi-
fications play critical roles in regulating various proteinfunctions. The consequences can be the alteration of pro-
tein structure, stability, subcellular localization, or even
protein activities. The Tat protein of HIV-1 has been dem-
onstrated to be modulated by a variety of posttranslational
modifications [22]. Prior to our study, Tat has been re-
ported to undergo lysine 63-linked ubiquitination that
does not affect Tat stability [2]. However, according to our
results, Tat is modified by lysine 48-linked polyubiquitin
chains and targeted to proteasome-dependent degrad-
ation. The divergence is probably due to the fact that the
plasmids encoding ubiquitin mutants used in the two
studies are different. That is, the ubiquitin mutants used
in their study contain a single lysine mutation, while ours
maintain only one lysine with all the others mutated to ar-
ginine. Multipoint mutation may affect the occurrence of
certain types of ubiquitination. Although the lysine 29- or
63-linked ubiquitination of Tat failed to be detected,
cotransfection with one of the two mutants definitely
Zhang et al. Cell & Bioscience 2014, 4:61 Page 9 of 11
http://www.cellandbioscience.com/content/4/1/61affected Tat activities. Nevertheless, we could not rule out
the possibility that overexpression of ubiquitin could influ-
ence the interaction partners of Tat, which indirectly con-
tributes to the regulatory effects on Tat.
Our study also shows that the amount of Tat72 was
increased after MG132 treatment, whereas Tat86 showed
little response. The sequences of these two truncated
forms are identical apart from the presence of a RGD
motif at the carboxyl-terminal region of Tat86, whose
well-characterized role is to enable Tat protein to bind
cell membranes [30]. Although there is no evidence of a
correlation between the RGD motif and proteasome-
dependent degradation of Tat proteins, the difference of
the two truncated proteins in response to MG132 treat-
ment is as a result of the additional RGD motif of Tat86.
The protein structure may be changed by the addition of
the RGD motif, which may further interfere the inter-
action between Tat86 and its E3 ubiquitin ligases and
affect the protein stability.
In our study, although the subcellular localization of
Tat was not influenced by coexpression with various ubi-
quitin mutants, the transactivation activity was affected
to varying degrees. A previous study has reported that
lysine 63-linked ubiquitination of Tat increases its trans-
activation activity [2]. We did not observe that type of
ubiquitination on Tat, but cotransfection with ubiquitin-
K63 mutant did promote Tat-mediated transactivation.
Lysine 48-linked ubiquitination of Tat remarkably en-
hanced its transactivation activity in the presence of the
proteasome inhibitor MG132, which indicates that the
ubiquitin-proteasome system is involved in the regulation
of Tat-mediated transactivation. In the ubiquitin-WT
cotransfection groups, the changes of Tat transactiva-
tion activity caused by MG132 treatment were not sig-
nificant, which might be due to competitive inhibition of
lysine 48-linked ubiquitination and proteasome-dependent
degradation of Tat by the other lysines in wild-type
ubiquitin.
Additionally, the transactivation activity of Tat appears
to be exquisitely regulated by its carboxyl-terminal re-
gion. Our data reveal that the transactivation activity of
full-length Tat is higher than that of Tat86, which con-
curs with previous reports [19], but lower than that of
Tat72. Only the transactivation activity of Tat72 was
strikingly enhanced by the addition of MG132.
Besides the well-known transactivation activity, Tat also
exerts a variety of other biological activities such as induc-
tion of apoptosis. According to the previously published
studies, Tat-induced apoptosis does not correlate with its
transactivation activity towards the HIV-1 LTR [19]. In
agreement with these findings, our results show that there
is no apparent correlation between these two functions of
the three forms of Tat or when the full-length Tat was
cotransfected with various ubiquitin plasmids.Several studies have reported that Tat promotes the
killing of cells by targeting the microtubule network
[23,25-29]. Tat can directly interact with tubulin dimers
and polymerized microtubules, which results in the ab-
normal stabilization of microtubules and the disturbance
of microtubule dynamics [26,28]. It has been shown pre-
viously that the four residues (36–39) of Tat are neces-
sary and sufficient for its interaction with tubulin [26].
We additionally demonstrate that the carboxyl-terminal
region of Tat does have some impact on this interaction.
However, Tat-induced apoptosis does not entirely result
from its microtubule-stabilizing abilities. Among the
three forms of Tat, Tat72, the form generated in the late
stage of HIV-1 infection cycle, has the weakest activity
towards microtubule assembly but induces the most ro-
bust apoptosis, which may promote the progression of
infection and lead to pathogenesis of the acquired im-
munodeficiency syndrome (AIDS). Coexpression with
various ubiquitin mutants definitely affects Tat-induced
apoptosis and its activity towards microtubule assembly,
but there is no apparent correlation between the two
aspects.
Conclusions
Tat, a multidomain and multifunction protein, plays vital
roles in HIV-1 replication cycle and the pathogenesis of
AIDS [17,31,32]. The present study reveals that trunca-
tion of the carboxyl-terminal region of Tat leads to func-
tional differences. Thus, it is important to give sufficient
consideration to the carboxyl-terminal region of Tat in
future researches. As reported previously, a large num-
ber of transcription factors are regulated by ubiquitin-
proteasome system [33]. Our study adds Tat to the list.
The stability and activities of Tat are modulated by ubiqui-
tination. Although a variety of posttranslational modifica-
tions have been reported to occur on Tat [22], their exact
effects are far from fully characterization. Targeting Tat
posttranslational modifications may represent a new and
unique therapy for HIV-1 sufferers. As evidenced by pub-
lications, Tat acetylation is a dynamic and highly regulated
process during HIV-1 infection [4,9,10,12,14]. Locking Tat
in one modified state may diminish or even abolish Tat ac-
tivities which are essential for HIV-1 infection and AIDS
progression. Maybe this strategy can be applied to other
types of Tat posttranslational modifications that will facili-
tate AIDS treatment.
Materials and methods
Antibodies and plasmid constructs
Antibodies against GFP (Roche), Myc (Sigma-Aldrich),
α-tubulin (Abcam), and cleaved caspase-3 (Cell Signal-
ing Technology), horseradish peroxidase-conjugated
secondary antibodies (Amersham Biosciences), and
rhodamine-conjugated secondary antibodies (Jackson
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indicated sources. The mammalian expression plasmid for
GFP-Tat101 was constructed by cloning HIV-1 Tat cDNA
into the pEGFPC1 vector, and the truncated forms, GFP-
Tat86 and GFP-Tat72, were generated by insertion of the
cDNA fragments into the pEGFPC1 vector. The His-Myc-
ubiquitin expression plasmid was kindly provided by
Ceshi Chen (Kunming Institute of Zoology, Chinese
Academy of Sciences), and the K0, K29, K48, and K63
mutants were generated by site-directed mutagenesis.
The ubiquitin-K0 mutant contains no lysine, and the
ubiquitin-K29, -K48, and -K63 mutants contain only a
single lysine (K29, K48, and K63, respectively), with all
the other lysines mutated to arginine. The HIV-1 long
terminal repeat (LTR)-driven luciferase plasmid has
been described previously [14]. All plasmids were veri-
fied by DNA sequencing.Cell transfection and treatment
293 T cells and HeLa cells were obtained from the
American Type Culture Collection. Plasmids were
transfected to 293 T cells by using the polyethylenei-
mine reagent (Polysciences) and transfected to HeLa
cells by using Entranster™-D (Engreen Biosystem). For
the inhibition of proteasome, 5 μM MG132 (Sigma-
Aldrich) was added into the culture medium and cells
were incubated for additional 8 hours unless indicated
otherwise.Quantitative real-time PCR analysis
293 T cells transfected with GFP-Tat101, GFP-Tat86, or
GFP-Tat72 were treated with (+) or without (−) MG132.
Total RNA was isolated from the cells using the TRIzol
reagent (Invitrogen) according to the manufacturer’s in-
struction. The isolated RNA was reverse-transcribed into
cDNA by reverse transcriptase (Promega). The following
primer sequences (listed later) were used. Quantitative
real-time PCR reactions were performed using SYBR
green master mix (BioRad) with an Eppendorf realplex.
Primers used were as follows. Tat-forward, GTTTGTT
TCACAAAAAAAGGCTTAG, Tat-reverse, CTAGTTTA
GGATCTACTGGCTCCAT; human GAPDH-forward,
ATCACTGCCACCCAGAAGAC, human GAPDH-reverse,
ATGAGGTCCACCACCCTGTT.Preparation of soluble and polymeric tubulin
HeLa cells were lysed in the PEMT buffer (100 mM
PIPES, 1 mM EGTA, 1 mM MgSO4, 1 mM GTP, 4 M
glycerol, 0.5% Triton X-100, pH 6.8), and the supernatant
was then collected as soluble tubulin. The remaining poly-
meric fraction was dissolved in 2% SDS in 50 mM Tris,
pH 6.8.Immunoblot analysis and immunoprecipitation
Protein samples were resolved by SDS-PAGE and
transferred onto polyvinylidene difluoride membranes
(Millipore). The membranes were blocked with 5% fat-free
milk in Tris-buffered saline containing 0.1% Tween 20
and incubated with primary antibodies followed by horse-
radish peroxidase-conjugated secondary antibodies. Specific
proteins were visualized with enhanced chemiluminescence
detection reagent following the manufacturer’s instructions
(Pierce Biotechnology). For immunoprecipitation, pro-
tein samples were incubated with anti-GFP antibody-
conjugated agarose beads (MBL) at 4°C overnight. The
beads were washed extensively and subjected to immu-
noblot analysis.Immunofluorescence microscopy
HeLa cells grown on glass coverslips were fixed with 4%
paraformaldehyde for 30 minutes at room temperature
followed by permeabilization with 0.5% Triton X-100 in
PBS for 20 minutes. Cells were then blocked with 2%
bovine serum albumin in PBS for 30 minutes and incu-
bated in succession with the primary antibody and
rhodamine-conjugated secondary antibody followed by
staining with DAPI (Sigma-Aldrich) for 3 minutes. Cover-
slips were mounted with 90% glycerol in PBS and images
were obtained using an Axio Observer A1 fluorescence
microscope (Carl Zeiss Inc).Luciferase reporter assay
Plasmids to be detected were cotransfected with the
HIV-1 LTR-driven luciferase plasmid to 293 T cells.
24 hours post-transfection, the fluorescence of GFP was
examined by using the fluorescence microscope, and the
intensity of GFP-tagged proteins was assessed via ImageJ
software. Cells were then lysed and the transactivation
activity was measured with an FB12 luminometer (Bert-
hold Detection Systems) and normalized to GFP intensity.Apoptosis analysis
HeLa cells were examined under the fluorescence
microscope 96 hours post-transfection, and both phase
contrast and fluorescence images were taken. The per-
centage of apoptotic cells was quantified by analyzing cell
morphology of the GFP-positive cells. Additionally, apop-
totic cells were also examined and quantified by Annexin
V-APC (BioLegend) staining coupled with flow cytometry.Statistical analysis
Analysis of statistical significance was performed by
two-tailed Student’s t-test using GraphPad Prism 5.
*P < 0.05, **P <0.01, ***P < 0.001; ns, not significant.
Data represent means ± SD.
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